Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
5 studies found for:    21526923 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting Safety and Efficacy of Two Regimens of Ranibizumab 0.5 mg in Chinese Patients With Neovascular AMD
Condition: Neovascular Age-related Macular Degeneration
Interventions: Procedure: 1+PRN;   Procedure: 3+PRN;   Drug: Ranibizumab
2 Recruiting Treat-and-extend Regimen of Aflibercept in Diabetic Macular Edema (VIBIM Study)
Condition: Macular Edema, Diabetic
Intervention: Drug: aflibercept
3 Active, not recruiting Treat & Extend Treatment With 0.5mg Ranibizumab vs Monthly Treatment With 0.5mg Ranibizumab
Condition: Macular Degeneration
Intervention: Drug: 0.5mg ranibizumab
4 Completed Study for Recalcitrant Age Related Macular Degeneration
Condition: Age Related Macular Degeneration
Intervention: Drug: aflibercept 2.0 mg
5 Active, not recruiting
Has Results
Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial
Condition: Age Related Macular Degeneration
Interventions: Drug: ranibizumab;   Drug: bevacizumab

Indicates status has not been verified in more than two years